4.8 Review

Tertiary Lymphoid Structures in the Central Nervous System: Implications for Glioblastoma

期刊

FRONTIERS IN IMMUNOLOGY
卷 12, 期 -, 页码 -

出版社

FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2021.724739

关键词

tertiary lymphoid structure; immunotherapy; glioma; central nervous system; brain; glioblastoma

资金

  1. Swedish Cancer Society [CAN 2015/1216, 20 1008 PjF, 20 1010 UsF, 190184Pj]
  2. Swedish Childhood Cancer Fund [TJ 2019-0014, PR2018-0148, PR2020-0167]
  3. Swedish Research Council [2020-02563, 2019-01326]
  4. Knut and Alice Wallenberg foundation [KAW 2019.0088]
  5. Vinnova [2019-01326] Funding Source: Vinnova
  6. Swedish Research Council [2019-01326, 2020-02563] Funding Source: Swedish Research Council
  7. Formas [2019-01326] Funding Source: Formas

向作者/读者索取更多资源

Glioblastoma is an aggressive brain tumor with a low prevalence of tumor-reactive T cells, and recent data suggest that naive T cells may be activated within brain tumor-associated tertiary lymphoid structures. Promoting tertiary lymphoid structures could enhance priming of tumor antigen-targeted T cells and sensitize glioblastomas to cancer immunotherapy.
Glioblastoma is the most common and aggressive brain tumor, which is uniformly lethal due to its extreme invasiveness and the absence of curative therapies. Immune checkpoint inhibitors have not yet proven efficacious for glioblastoma patients, due in part to the low prevalence of tumor-reactive T cells within the tumor microenvironment. The priming of tumor antigen-directed T cells in the cervical lymph nodes is complicated by the shortage of dendritic cells and lack of appropriate lymphatic vessels within the brain parenchyma. However, recent data suggest that naive T cells may also be primed within brain tumor-associated tertiary lymphoid structures. Here, we review the current understanding of the formation of these structures within the central nervous system, and hypothesize that promotion of tertiary lymphoid structures could enhance priming of tumor antigen-targeted T cells and sensitize glioblastomas to cancer immunotherapy.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

LGR5 promotes tumorigenicity and invasion of glioblastoma stem-like cells and is a potential therapeutic target for a subset of glioblastoma patients

Yuan Xie, Anders Sundstrom, Naga P. Maturi, E-Jean Tan, Voichita D. Marinescu, Malin Jarvius, Malin Tirfing, Chuan Fin, Lei Chen, Magnus Essand, Fredrik J. Swartling, Sven Nelander, Yiwen Jiang, Lene Uhrbom

JOURNAL OF PATHOLOGY (2019)

Review Oncology

Virus-Based Immunotherapy of Glioblastoma

Miika Martikainen, Magnus Essand

CANCERS (2019)

Article Hematology

TARP is an immunotherapeutic target in acute myeloid leukemia expressed in the leukemic stem cell compartment

Barbara Depreter, Karin E. Weening, Karl Vandepoele, Magnus Essand, Barbara De Moerloose, Maria Themeli, Jacqueline Cloos, Diana Hanekamp, Ine Moors, Inge D'hont, Barbara Denys, Anne Uyttebroeck, An Van Damme, Laurence Dedeken, Sylvia Snauwaert, Glenn Goetgeluk, Stijn De Munter, Tessa Kerre, Bart Vandekerckhove, Tim Lammens, Jan Philippe

HAEMATOLOGICA (2020)

Article Cell & Tissue Engineering

Humanized Stem Cell Models of Pediatric Medulloblastoma Reveal an Oct4/mTOR Axis that Promotes Malignancy

Matko Cancer, Sonja Hutter, Karl O. Holmberg, Gabriela Rosen, Anders Sundstrom, Jignesh Tailor, Tobias Bergstrom, Alexandra Garancher, Magnus Essand, Robert J. Wechsler-Reya, Anna Falk, Holger Weishaupt, Fredrik J. Swartling

CELL STEM CELL (2019)

Article Cell Biology

Characterization of virus-mediated immunogenic cancer cell death and the consequences for oncolytic virus-based immunotherapy of cancer

Jing Ma, Mohanraj Ramachandran, Chuan Jin, Clara Quijano-Rubio, Miika Martikainen, Di Yu, Magnus Essand

CELL DEATH & DISEASE (2020)

Article Immunology

Astrocytes have the capacity to act as antigen-presenting cells in the Parkinson's disease brain

Jinar Rostami, Grammatiki Fotaki, Julien Sirois, Ropafadzo Mzezewa, Joakim Bergstrom, Magnus Essand, Luke Healy, Anna Erlandsson

JOURNAL OF NEUROINFLAMMATION (2020)

Article Chemistry, Multidisciplinary

Development of a New Hyaluronic Acid Based Redox-Responsive Nanohydrogel for the Encapsulation of Oncolytic Viruses for Cancer Immunotherapy

Siyuan Deng, Alessandra Iscaro, Giorgia Zambito, Yimin Mijiti, Marco Minicucci, Magnus Essand, Clemens Lowik, Munitta Muthana, Roberta Censi, Laura Mezzanotte, Piera Di Martino

Summary: A redox responsive nanohydrogel based on hyaluronic acid was developed as a delivery system for oncolytic viruses, showing rapid degradation in a reductive environment and good oncolytic activity. Due to its hydrophilic and porous nature, the nanohydrogel is considered a promising carrier for viral drugs.

NANOMATERIALS (2021)

Article Cardiac & Cardiovascular Systems

Perivascular Macrophages Regulate Blood Flow Following Tissue Damage

Evelina Vagesjo, Kristel Parv, David Ahl, Cedric Seignez, Carmen Herrera Hidalgo, Antoine Giraud, Catarina Leite, Olle Korsgren, Hakan Wallen, Greta Juusola, Harri H. Hakovirta, Helene Rundqvist, Magnus Essand, Lena Holm, Randall S. Johnson, Charlotte Thalin, Petra Korpisalo, Gustaf Christoffersson, Mia Phillipson

Summary: This study reveals a novel role of macrophages in regulating blood flow by releasing iNOS in ischemic muscles to improve tissue perfusion and repair. Depletion of iNOS in macrophages compromised blood flow regulation and exacerbated ischemic damage in the muscles.

CIRCULATION RESEARCH (2021)

Article Multidisciplinary Sciences

Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma

Luuk van Hooren, Alessandra Vaccaro, Mohanraj Ramachandran, Konstantinos Vazaios, Sylwia Libard, Tiarne van de Walle, Maria Georganaki, Hua Huang, Ilkka Pietilae, Joey Lau, Maria H. Ulvmar, Mikael C. I. Karlsson, Maria Zetterling, Sara M. Mangsbo, Asgeir S. Jakola, Thomas Olsson Bontell, Anja Smits, Magnus Essand, Anna Dimberg

Summary: This study demonstrates that the use of immunostimulatory CD40 antibodies in glioma models promotes the formation of tertiary lymphoid structures but does not improve survival and impairs the response to immune checkpoint blockade.

NATURE COMMUNICATIONS (2021)

Article Oncology

IFN-I-tolerant oncolytic Semliki Forest virus in combination with anti-PD1 enhances T cell response against mouse glioma

Miika Martikainen, Mohanraj Ramachandran, Roberta Lugano, Jing Ma, Minttu-Maria Martikainen, Anna Dimberg, Di Yu, Andres Merits, Magnus Essand

Summary: The study constructed an IFN-I-resistant SFV-AM6 virus that induced immunogenic apoptosis in GL261 cells and showed therapeutic potency against glioma. Additionally, combination therapy with SFV-AM6-124T and antiPD1 immunotherapy promoted an inflammatory response and increased tumor-reactive CD8(+) cells in the GL261 glioma model.

MOLECULAR THERAPY-ONCOLYTICS (2021)

Article Nanoscience & Nanotechnology

Targeting circulating monocytes with CCL2-loaded liposomes armed with an oncolytic adenovirus

Alessandra Iscaro, Christian Jones, Neil Forbes, Amina Mughal, Faith Nutter Howard, Haider Al Janabi, Secil Demiral, Yvonne Perrie, Magnus Essand, Aleksandra Weglarz, Luis J. Cruz, Claire E. Lewis, Munitta Muthana

Summary: This study demonstrates that encapsulating oncolytic adenovirus into CCL2-coated liposomes can effectively target tumors by recruiting circulating monocytes expressing CCR2. The nanomedicine approach significantly reduces tumor size and metastasis, providing a potential strategy for treating inaccessible tumors.

NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2022)

Article Biotechnology & Applied Microbiology

Ixovex-1, a novel oncolytic E1B-mutated adenovirus

Mohiemen Anwar, Maja-Louise Arendt, Mohanraj Ramachandran, Anette Carlsson, Magnus Essand, Goran Akusjarvi, Ghasan Alusi, Daniel Oberg

Summary: This research describes a novel oncolytic adenovirus, Ixovex-1, which selectively replicates within cancer cells by modulating the level of expression of different E1B mRNA isoforms. The study demonstrates the characteristics and anti-tumor efficacy of Ixovex-1 in both in vitro and in vivo experiments, showing its superiority compared to other viruses with multiple deletions.

CANCER GENE THERAPY (2022)

Article Engineering, Biomedical

CAR T cells expressing a bacterial virulence factor trigger potent bystander antitumour responses in solid cancers

Chuan Jin, Jing Ma, Mohanraj Ramachandran, Di Yu, Magnus Essand

Summary: CAR T cells expressing NAP from Helicobacter pylori can trigger endogenous bystander T-cell responses against solid cancers, improving tumor growth and survival rates.

NATURE BIOMEDICAL ENGINEERING (2022)

Article Oncology

Tumor endothelial cell up-regulation of IDO1 is an immunosuppressive feed-back mechanism that reduces the response to CD40-stimulating immunotherapy

Maria Georganaki, Mohanraj Ramachandran, Sander Tuit, Nicolas Gonzalo Nunez, Alexandros Karampatzakis, Grammatiki Fotaki, Luuk van Hooren, Hua Huang, Roberta Lugano, Thomas Ulas, Aura Kaunisto, Eric C. Holland, Peter Ellmark, Sara M. Mangsbo, Joachim Schultze, Magnus Essand, Sonia Tugues, Anna Dimberg

ONCOIMMUNOLOGY (2020)

暂无数据